menu
    • menu
    [{"orgOrder":0,"company":"Cytovation","sponsor":"Norwegian Cancer Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"CY-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Norwegian Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Norwegian Cancer Society"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CyPep-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CyPep-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Merck & Co"},{"orgOrder":0,"company":"Cytovation","sponsor":"Recurrent Respiratory Papillomatosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CyPep-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Recurrent Respiratory Papillomatosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Recurrent Respiratory Papillomatosis Foundation"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"CyPep-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"CyPep-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2025","type":"Financing","leadProduct":"CyPep-1","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"}]

    Find Clinical Drug Pipeline Developments & Deals by Cytovation

    Menu

    Cytovation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sandwater

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cytovation Raises $6M to Advance CY-101 Phase 2 in Adrenocortical Cancer

                            Details : The financing will be used to advance CY-101 (CyPep-1), a membranolytic inhibitor of the Wnt/beta-catenin pathway. It is being evaluated for the treatment of Adrenocortical Carcinoma.

                            Product Name : CY-101

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            April 23, 2025

                            Lead Product(s) : CyPep-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sandwater

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CY-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Norwegian Cancer Society

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cancer Research UK, Cytovation, Norwegian Cancer Society Collaborate on Rare Cancer

                            Details : The collaboration aims to bring Cytovation’s lead asset, CY-101, into a multi-national clinical trial for patients with adrenocortical carcinoma.

                            Product Name : CY-101

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            January 23, 2025

                            Lead Product(s) : CY-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Norwegian Cancer Society

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors

                            Details : CyPep-1 is a chemically synthesized peptide with oncolytic properties. It selectively targets cancer cells based on their altered molecular composition and releases tumor neoantigens to the microenvironment which potentially induces an anti-tumour immune...

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 10, 2023

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytovation Announces First Patient Dosed in Phase 2a Study Investigating CyPep-1 Monotherapy in Advanced Melan...

                            Details : CyPep-1 is a chemically synthesized peptide with oncolytic properties. It selectively targets cancer cells based on their altered molecular composition and releases tumor neoantigens to the microenvironment which potentially induces an anti-tumour immune...

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 15, 2023

                            Lead Product(s) : CyPep-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sandwater

                            Deal Size : $8 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Cytovation Raises $8 Million in Series A Extension Financing Round for Clinical Advancement Of CyPep-1, A Firs...

                            Details : The net proceeds will support the progress of Cytovation’s lead asset, CyPep-1, a first-in-class immunotherapy targeting the cell membrane of tumor cells, into a full Phase 2 program for the treatment of solid tumors.

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 06, 2023

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sandwater

                            Deal Size : $8 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Recurrent Respiratory Papillomatosis Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cytovation Collaborates with Recurrent Respiratory Papillomatosis Foundation to Expand Its Clinical Investigat...

                            Details : The collaboration will enable Cytovation to draw upon RRPF’s extensive knowledge and network in preparation for a Phase I/II study to investigate CyPep-1 in RRP to be initiated in 2H 2022.

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 02, 2022

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Recurrent Respiratory Papillomatosis Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US FDA Accepts Cytovation's IND Application For Phase II Combination Studies of CyPep-1, a First-In-Class Targ...

                            Details : CyPep-1 eliminates cancer cells by forming pores in the plasma membrane, releasing cancer specific antigens to the immune system, promoting an inflammatory microenvironment and inducing a tumor-specific immune response by in situ vaccination.

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 19, 2022

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sandwater

                            Deal Size : $20.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Cytovation Raises $20 Million in Series a Financing Round to Advance Clinical Development of CyPep-1, a First-...

                            Details : The new funds will primarily be directed towards clinical development of Cytovation's lead asset CyPep-1, a proprietary first-in-class targeted tumor membrane immunotherapy engineered to selectively target cancer cells.

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 25, 2022

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sandwater

                            Deal Size : $20.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed with CyPep-1 in Combination with KEYTRUDA® in Cytovation's Ph I/IIa CICILIA Clinical Tria...

                            Details : CyPep-1, is a targeted tumor membrane immunotherapy engineered to selectively target tumor cell membranes based on their altered molecular composition relative to normal cells. Preclinical data suggest this mode of action is highly synergistic with check...

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 15, 2021

                            Lead Product(s) : CyPep-1,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Cytovation

                            Norway arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CyPep-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CyPep-1 Shows Preliminary Safety, Tolerability and Early Signs of Efficacy in Part 1 of its Ph I/IIa CICILIA T...

                            Details : CyPep-1 is proprietary first-in-class tumorolytic agent engineered to selectively target tumor cell membranes. Monotherapy and combination with KEYTRUDA is intended to progress to Phase II program in patients with melanoma.

                            Product Name : CyPep-1

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 23, 2021

                            Lead Product(s) : CyPep-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth